G Ricolleau
Overview
Explore the profile of G Ricolleau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
149
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Loussouarn D, Campion L, Leclair F, Campone M, Charbonnel C, Ricolleau G, et al.
Br J Cancer
. 2009 Jun;
101(1):166-73.
PMID: 19513072
Background: We recently identified and validated UBE2C RNA as a prognostic marker in 252 node-positive (N+) breast cancers by means of a microarray study. The aim of this study was...
2.
Riedinger J, Bonnetain F, Basuyau J, Eche N, Larbre H, Dalifard I, et al.
Ann Oncol
. 2007 Feb;
18(5):881-5.
PMID: 17301071
Background: CA 125 assays enable treatment response monitoring in ovarian cancer. Patients And Methods: This multicentric study was carried out to assess the prognostic value of the CA 125 change...
3.
Riedinger J, Wafflart J, Ricolleau G, Eche N, Larbre H, Basuyau J, et al.
Ann Oncol
. 2006 Jun;
17(8):1234-8.
PMID: 16766592
Background: CA 125 assays enable treatment-response monitoring in ovarian cancer. Patients And Methods: A multicentric study of CA 125 kinetics under induction chemotherapy was performed in 631 patients. CA 125...
4.
Jezequel P, Pichon J, Magrangeas F, Minvielle S, Millour M, Ricolleau G, et al.
Ann Biol Clin (Paris)
. 2004 Jun;
62(3):361-6.
PMID: 15217774
Manufacturing and using DNA chips in a laboratory, while respecting legality and good practices, require a review of the regulatory framework and relevant documentation for implementing a quality assurance system....
5.
Jezequel P, Campion L, Joalland M, Millour M, Dravet F, Classe J, et al.
Br J Cancer
. 2004 Jan;
90(1):189-93.
PMID: 14710228
This study screened large cohorts of node-positive and node-negative breast cancer patients to determine whether the G388R mutation of the FGFR4 gene is a useful prognostic marker for breast cancer...
6.
Broet P, Romain S, Daver A, Ricolleau G, Quillien V, Rallet A, et al.
J Clin Oncol
. 2001 Jun;
19(11):2778-87.
PMID: 11387348
Purpose: To assess the prognostic value of thymidine kinase (TK), an enzyme involved in the DNA synthesis salvage pathway, relative to other prognostic factors in primary breast cancer. Patients And...
7.
Jezequel P, Joalland M, Milano G, Lanoe D, Ricolleau G, Deporte-Fety R
Clin Chem
. 2000 Feb;
46(2):309-10.
PMID: 10657402
No abstract available.
8.
Broet P, Spyratos F, Romain S, Quillien V, Daver A, Ricolleau G, et al.
Br J Cancer
. 1999 Jul;
80(3-4):536-45.
PMID: 10408864
The purpose of this retrospective multicentre study was to assess the prognostic value of urokinase plasminogen activator (uPA) and p53 levels in a large series of primary breast cancer, using...
9.
Koscielny S, Terrier P, Daver A, Wafflart J, Goussard J, Ricolleau G, et al.
Eur J Cancer
. 1998 Aug;
34(4):476-81.
PMID: 9713296
The purpose of this prospective multicentric study was to quantify the c-erbB-2 protein and investigate its relationship with DNA amplification and with various prognostic parameters of breast cancer. A total...
10.
Clement M, Bischof P, Gruffat C, Ricolleau G, Auvray E, Quillien V, et al.
Int J Cancer
. 1995 Jan;
60(2):199-203.
PMID: 7829216
The ELSA-CA 125 II is a second-generation radioimmunoassay for the quantification of CA 125 in serum. In a multicentre study involving 49 follow-ups of patients with ovarian cancers, and 880...